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The next line of defence against antibiotic-
resistant bacteria could be genetically modified 
viruses. If bacteriophage, viruses that replicate 
by infecting bacterial cells, are engineered with 
genetic programing to target bacteria that harm 
humans, a large amount of time and money 
could be saved by no longer adapting antibiotics 
to evolving bacteria. Using phage as a form of 
medicine is called Phage Therapy. But that is not 
the only application for phage technology, phage 
can be adapted to initiate cell death through ge-
netic codes, or gene expression for cells that do 
not use certain beneficial genes. Conventional 
antibiotics affect more types of cells than are 
necessary to cure illnesses and thus produce 
harmful side effects. Phage therapy can be used 
to sterilize food, treat infection, stimulate gene 
expression, and perhaps much more.
 
La prochaine ligne de défense contre les bac-
téries résistantes aux antibiotiques pourrait être 
les virus génétiquement modifiés. Si la bacté-
riophage, un virus qui se répliquent en infectant 
des cellules bactériennes, sont conçus avec la 
programmation génétique pour cibler les bacté-
ries qui infectent humains, beaucoup de temps et 
d'argent pourrait être économisé en n'adaptant 
plus les antibiotiques a l'évolution des bactéries. 
On s'appele cette utilization medicinale de phage 
«Phagothérapie». Mais ce n'est pas la seule ap-
plication de la technologie de phage, ca peut être 
adapté pour déclencher la mort des cellules par 
des codes génétiques ou par l'expression des 
gènes des cellules qui n'utilisent pas de certains 
gènes bénéfiques. Antibiotiques classiques af-
fectent plusieurs types de cellules, plus qui est 
nécessaire pour guérir les maladies, et donc 
ils produisent les effets secondaires néfastes. 
Phage thérapie peut être utilisé pour la stérili-
sation d'aliments, traiter des infections, stimuler 
l'expression du gène, et peut-être beaucoup plus.
Introduction
Antibiotic resistant bacterium is one of the most 
pressing issues in modern medicine. Bacterial spe-
cies evolve through the use and misuse of antibiot-
ics to withstand those medications, forcing the use 
of either stronger and more harmful antibiotics or 
an alternate medication. Some of the first published 
findings on Bacteriophage (commonly referred to 
as phage(s)) were presented by Felix d’Herelle at 
the Academy of Sciences in September of 1917[1], 
though microbiologists and physicians had observed 
them before. 
Bacteriophage (bacteria eaters) are viruses that 
attach to the cell membrane of a bacterium and insert 
their genetic material, carried in the ‘head’ of the virus 
into the bacterium. This genetic material carries the 
information necessary for the cell to construct a copy 
of the virus. The bacteria cellular machinery express-
es the genetic material of the phage like any other 
piece of genetic information. Then the cell begins to 
build more phage. 
The viruses are eventually released either by exit-
ing through small rips in the cell membrane, or from 
the cell rupturing completely.
Phage therapy is the process of utilizing these 
phage to our own advantage by introducing them to 
patients with bacterial infections. Thus allowing the 
viruses to multiply and destroy the problem cells. 
Effectiveness
Antibiotics have been the preferred method of 
treatment against bacterial infections despite the use 
of phage therapy being shown as a viable medica-
tion even before using antibiotics. This is due to the 
lower costs and higher speed of developing antibiot-
ics as opposed to phage therapy. However with the 
discovery of the many side effects associated with 
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Antibiotics are poisons that work in a number of 
ways to kill cells, but they are not selective and will 
affect any and all cells they come into contact with. 
In comparison, bacteriophage chemically bind to the 
cell membranes of specific bacterium and will not 
affect other types of cells. Although human trials of 
phage therapy are extremely rare in the Americas 
and Europe, a large number of studies have been 
conducted in vitro, as well as a number in vivo; usu-
ally in mice. One such study by H. Williams Smith 
and M. B. Huggins at the Houghton Poultry Research 
Station focused specifically on comparing the effec-
tiveness of phage therapy against traditional anti-
biotics in live mice infected with Escherichia coli[2].
In the study, multiple groups of 32 mice were in-
fected intracerebrally with the same dosage of E. coli 
and received different treatments for the lethal infec-
tion. Out of 5 antibiotics used to cure the infection 
only Streptomycin was significantly effective. How-
ever, it was only when using eight times the normal 
dosage (200mg instead of 25mg) that the antibiotic 
was on par with the effectiveness of a single dose 
of phage (3x108 viable particles). Afterwards the re-
maining mice were tested for residual brain damage 
and it was found that about 43% more mice experi-
enced damage to the cerebellum if they received the 
antibiotics as opposed to the phage. These findings 
show the effectiveness of phage therapy but also their 
overall safety compared to traditional antibiotics[2].
Streptomycin in particular, has been widely mis-
used in the past, and was documented to often 
cause vestibular damage. Even more harmful medi-
cations have been used, such as neomycin, which 
has been known to cause complete deafness even 
when using smaller doses than other antibiotics[3].
Application
Phage therapy can be applied to a wide range of 
tasks such as: curing infections, sterilizing meats, 
and studying genetic processes. In 2008 Aiden J. 
Synnott conducted a study at the Tokyo Institute of 
Technology, into the use of phage therapy to cure 
bovine mastitis – a large-scale problem in the dairy 
industry due to the high cost of antibiotic treat-
ment and the removal of beneficial bacterium. The 
team tested raw milk from cows with mastitis isolat-
ing multiple strains of Staphylococcus aureus, and 
screened for potentially lytic phage from munici-
pal wastewater in order to perform the experiment.
After obtaining 49 different isolates of S. aureus 
from the milk samples, the researchers screened 
52 different phage types for high lytic activity to
wards S. aureus. By repeatedly spotting the phage 
onto lawns of S. aureus isolates and selecting the 
most effective isolates (phage that created the most 
distinct clearing zones) they were able to narrow 
down the most lytic phage, and the phage that af-
fected multiple strains of the mastitis causing bac-
teria. Eventually two phage were selected for analy-
ses because of their high lytic ability towards over 
half of the 15 isolates of S. aureus[4]. This study 
demonstrates yet another medical application of 
phage therapy, and how it could be used for the 
treatment of lethal illnesses and common infections.
One of the problems with using a system such as 
phage therapy in an organism with an active immune 
system is the rejection of the phage particles by the 
host organism. In order for cells to identify other cells, 
they carry polypeptides on their cell membranes as a 
sort of ‘ID tag’. This allows cells to distinguish between 
another cell of their species, a possible threat, or food. 
In the case of human immune systems, white 
blood cells use polypeptide tags to distinguish be-
tween our own cells, and cells of any other organism. 
When it comes to phage therapy this could poten-
tially cause problems where one’s immune system 
might reject the phage particles and destroy them 
before they can serve their purpose. Genetically 
engineering the phage to display different polypep-
tide tags may solve this problem, as well as open 
up other possible applications for phage therapy.
Figure 1. Diagram of a Bacteriophage Infecting a 
Cell (Steven M. Carr 2011 p 1)
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The genetic information carried by a phage codes 
for the construction of an exact copy of that phage. 
So if one alters that code they can alter the resulting 
phage that are constructed. 
It has been shown that the changing of the surface 
polypeptides (phage display) can be extremely effec-
tive. Entirely artificial proteins have been successful-
ly implemented into bacteriophage for display[5]. This 
technology is useful because it allows phage parti-
cles to be disguised from other cells. After changing 
the displayed proteins, other cells may mistake it for 
another organism, even their own species. In phage 
therapy, this could allow for the hiding of bacterio-
phage from a patient’s immune system. Allowing the 
phage to operate unhindered as well as decreasing 
the number of doses that need to be administered.
Traditional phage therapy was the application of 
phage that were lytic against a particular bacterium. 
Another way to utilize bacteriophage is to genetically 
modify them to carry genetic information that will not 
affect the construction of more phage, but is used in 
the cells usual processes. That way each phage is 
a sort of messenger bringing genetic information to 
the cell. One possible application is to use a phage 
to deliver the genetic instructions for cell death to the 
cell , but there are almost limitless potential uses for 
this technology. 
Instead of fighting an infection this could allow 
the delivery of beneficial genetic information to a pa-
tient’s cells, letting them express some gene that is 
not normally expressed, or increasing how much it is 
expressed.
Conclusion
The use of phage therapy has an extremely wide 
range of applications, from treating infections to de-
livering genetic information. It has been shown to 
be immensely more efficient than antibiotics, and 
through the process of natural selection, whenever 
a strain of bacterium becomes resistant to the phage 
the process of finding a new lytic phage is extremely 
economic and quick (taking less than 48hrs and cost-
ing less than $1000). Unlike traditional antibiotics, 
phage therapy does not cause unwanted side effects 
as phage are selective of their targets and thus side 
effects are drastically reduced. 
Widely used to treat patients in Russia, the FDA 
has thus far only approved the use of phage therapy 
for sterilizing meats. The use of mass produced an-
tibiotics is going to come to a close. Perhaps phage 
therapy should be its replacement.
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